Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2025

6 - 8 Dec 2025

Orange County Convention Center, Orlando, United States of America

Non-TBI conditioning achieves 76% 2-year EFS in MRD-negative CAYA B-ALL...

Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA

Non-TBI conditioning achieves 76% 2-year EFS in MRD-negative CAYA B-ALL undergoing allogeneic HCT ( Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA )

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL: SWOG 1318 long-te ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL: E1910 phase III trial results ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to...

Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of...

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab ( Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland )

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

ASH 2025: Highlights

Dr Lore Gruenbaum - Chief Scientific Officer, Blood Cancer United

ASH 2025: Highlights ( Dr Lore Gruenbaum - Chief Scientific Officer, Blood Cancer United )

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential...

Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia ( Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France )

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in...

Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma ( Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA )

Rusfertide provides durable control of haematocrit and phlebotomy reduction in...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses...

Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia

$Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma ( Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia )$

MRD validated as a surrogate endpoint for survival in AML

Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA

MRD validated as a surrogate endpoint for survival in AML ( Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA )

Zamtocabtagene autoleucel improves event-free survival vs standard of care in...

Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL ( Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany )

Anitocabtagene autoleucel achieves deep and durable responses in relapsed...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

$Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )$

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

Exploring genomic insights in acute lymphoblastic leukaemia treatment

Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA

Exploring genomic insights in acute lymphoblastic leukaemia treatment ( Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA )

Talquetamab plus teclistamab shows promise in true extramedullary multiple...

Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma ( Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA )

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights...

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Racial disparities in AML: Black patients show inferior survival despite...

Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine...

Racial disparities in AML: Black patients show inferior survival despite similar cytogenetics and treatment response ( Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine, Baltimore, USA )

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Asciminib shows high molecular response, favourable safety in 2L CML-CP ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and...

Prof Jennifer Woyach - The Ohio State University, Columbus, USA

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for...

Prof Jennifer Woyach - The Ohio State University, Columbus, USA

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive...

Prof Robert Orlowski - The University of Texas MD Anderson Cancer Center...

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses ( Prof Robert Orlowski - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer